|
Belichenko, Pavel V; Madani, Rime; Rey-Bellet, Lorianne et al. (2016) An Anti-?-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome. PLoS One 11:e0152471
|
|
Nosheny, R L; Belichenko, P V; Busse, B L et al. (2015) Increased cortical synaptic activation of TrkB and downstream signaling markers in a mouse model of Down Syndrome. Neurobiol Dis 77:173-90
|
|
Ruparelia, Aarti; Pearn, Matthew L; Mobley, William C (2013) Aging and intellectual disability: insights from mouse models of Down syndrome. Dev Disabil Res Rev 18:43-50
|
|
Rodrigues, Elizabeth M; Weissmiller, April M; Goldstein, Lawrence S B (2012) Enhanced ýý-secretase processing alters APP axonal transport and leads to axonal defects. Hum Mol Genet 21:4587-601
|
|
Ruparelia, Aarti; Pearn, Matthew L; Mobley, William C (2012) Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome. Curr Opin Neurobiol 22:880-6
|
|
Sung, Kijung; Maloney, Michael T; Yang, Jingkun et al. (2011) A novel method for producing mono-biotinylated, biologically active neurotrophic factors: an essential reagent for single molecule study of axonal transport. J Neurosci Methods 200:121-8
|
|
Belichenko, Nadia P; Belichenko, Pavel V; Kleschevnikov, Alexander M et al. (2009) The ""Down syndrome critical region"" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci 29:5938-48
|
|
Wu, Chengbiao; Cui, Bianxiao; He, Lingmin et al. (2009) The coming of age of axonal neurotrophin signaling endosomes. J Proteomics 72:46-55
|
|
Salehi, A; Faizi, M; Colas, D et al. (2009) Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med 1:7ra17
|
|
Chial, Heidi J; Wu, Ruping; Ustach, Carolyn V et al. (2008) Membrane targeting by APPL1 and APPL2: dynamic scaffolds that oligomerize and bind phosphoinositides. Traffic 9:215-29
|
Showing the most recent 10 out of 61 publications
